Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share (GLTO)
CUSIP: 36322Q107
Q4 2021 13F Holders as of 31 Dec 2021
- Type / Class
- Equity / Common Stock, par value $0.00001 per share
- Shares outstanding
- 60,338,437
- Total 13F shares
- 10,056,300
- Share change
- -341,974
- Total reported value
- $30,470,000
- Price per share
- $3.03
- Number of holders
- 24
- Value change
- -$1,059,530
- Number of buys
- 11
- Number of sells
- 11
Quarterly Holders Quick Answers
What is CUSIP 36322Q107?
CUSIP 36322Q107 identifies GLTO - Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 36322Q107:
Top shareholders of GLTO - Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
6.8%
|
4,090,937
|
$14,686,000 | — | 30 Sep 2021 | |
| Novo Holdings A/S |
13F
|
Company |
4.1%
|
2,497,791
|
$8,967,000 | — | 30 Sep 2021 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.1%
|
1,286,007
|
$4,496,000 | — | 30 Sep 2021 | |
| Cormorant Asset Management, LP |
13F
|
Company |
1.9%
|
1,150,730
|
$4,131,000 | — | 30 Sep 2021 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.47%
|
283,100
|
$1,016,000 | — | 30 Sep 2021 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.4%
|
243,500
|
$874,000 | — | 30 Sep 2021 | |
| Laurion Capital Management LP |
13F
|
Company |
0.32%
|
194,852
|
$700,000 | — | 30 Sep 2021 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.25%
|
152,353
|
$547,000 | — | 30 Sep 2021 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.17%
|
102,900
|
$369,000 | — | 30 Sep 2021 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.14%
|
83,344
|
$299,000 | — | 30 Sep 2021 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.12%
|
73,316
|
$263,000 | — | 30 Sep 2021 | |
| STATE STREET CORP |
13F
|
Company |
0.07%
|
43,006
|
$154,000 | — | 30 Sep 2021 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.06%
|
37,467
|
$135,000 | — | 30 Sep 2021 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.05%
|
27,754
|
$99,000 | — | 30 Sep 2021 | |
| Virtu Financial LLC |
13F
|
Company |
0.04%
|
24,587
|
$88,000 | — | 30 Sep 2021 | |
| Marquette Asset Management, LLC |
13F
|
Company |
0.04%
|
24,135
|
$87,000 | — | 30 Sep 2021 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.03%
|
20,000
|
$72,000 | — | 30 Sep 2021 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.03%
|
19,006
|
$68,000 | — | 30 Sep 2021 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.02%
|
13,129
|
$47,000 | — | 30 Sep 2021 | |
| Migdal Insurance & Financial Holdings Ltd. |
13F
|
Company |
0.02%
|
10,400
|
$37,000 | — | 30 Sep 2021 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
10,061
|
$36,000 | — | 30 Sep 2021 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.01%
|
8,957
|
$32,000 | — | 30 Sep 2021 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
400
|
$1,000 | — | 30 Sep 2021 | |
| HARBOUR INVESTMENTS, INC. |
13F
|
Company |
0%
|
300
|
$1,000 | — | 30 Sep 2021 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
242
|
$1,000 | — | 30 Sep 2021 |
Institutional Holders of Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share (GLTO) as of Q4 2021
As of 31 Dec 2021,
Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share (GLTO) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
10,056,300 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Novo Holdings A/S, Cormorant Asset Management, LP, JANUS HENDERSON GROUP PLC, TWO SIGMA ADVISERS, LP, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, Laurion Capital Management LP, Anson Funds Management LP, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2021 vs Q3 2021 Across Filers
Q3 2021 holders
25
Q4 2021 holders
24
Holder diff
-1
| Investor | Q3 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q3 2021 Value $ | Q4 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.